Recent Updates
Recently added Catalysts
OGN Positive Sentiment

Samenvatting: Sun Pharma tekent definitieve overeenkomst voor de overname van Organon

Monday, April 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Sun Pharmaceutical Industries Limited has announced a definitive agreement to acquire Organon & Co. for $14.00 per share, totaling an enterprise value of $11.75 billion. This acquisition marks a significant strategic move for Sun Pharma, enhancing its portfolio in the biopharma sector. The transaction will be executed entirely in cash.
Price reaction · baseline $11.26 (2026-04-24 close) · 10 other OGN headline(s) in the window, move may be shared
day 0 close
+16.9%
day 1 · peak
+18.3%
day 3
+17.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sun Pharma has successfully reached a definitive agreement.
  • The acquisition represents a significant investment in Organon.
  • The transaction is fully cash-based, indicating strong financial backing.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+54%
120-day peak, hindsight
Typical move
3.1%
average across 5 past catalysts
Lead asset
MK0653A, ezetimibe simvastatin
Phase 3 · Type 2 Diabetes Mellitus

Full Press Release Details

MUMBAI, India & JERSEY CITY, N.J.--(BUSINESS WIRE)--Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (samen met zijn dochterondernemingen en/of geassocieerde ondernemingen, “Sun Pharma”) en Organon & Co. (NYSE: OGN) (“Organon”) hebben vandaag bekendgemaakt dat zij een definitieve overeenkomst hebben gesloten, waarbij Sun Pharma alle uitstaande aandelen van Organon zal verwerven voor US$ 14,00 dollar per aandeel. De transactie vindt volledig in contanten plaats met een ondernemingswaarde van US$ 11,75 miljard.
Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

Frequently Asked Questions

What is the acquisition price for Organon?

Sun Pharma will acquire Organon for $14.00 per share.

What is the total enterprise value of the deal?

The total enterprise value of the acquisition is $11.75 billion.

Is the transaction cash-based?

Yes, the transaction will be executed entirely in cash.

Who is acquiring Organon?

Sun Pharmaceutical Industries Limited is acquiring Organon.

ShareAdd on Google
Tags: OGN Viatris Investor Conferences Healthcare Sun Pharma Organon acquisition biopharma enterprise value
Last updated: Apr 27, 2026

Biotech snapshot

Cash runway
$1132M liquidity · $0M/mo burn
Low dilution risk
Lead asset
MK0653A, ezetimibe simvastatinPhase 3
Type 2 Diabetes Mellitus →

Catalyst track record

+54%
best trade around OGN's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for OGN.

See every catalyst's timing & PoA →